Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of diosmetin on young rats with high-fat diet-induced non-alcoholic fatty liver disease

Guoying Zhang , Yuewu Yan, Xujiao Feng

Department of Infectious Diseases, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China;

For correspondence:- Guoying Zhang Email: ytwus9@163.com

Accepted: 26 January 2021 Published: 28 February 2021

Citation: Zhang G, Yan Y, Feng X. Effect of diosmetin on young rats with high-fat diet-induced non-alcoholic fatty liver disease. Trop J Pharm Res 2021; 20(2):315-320 doi: 10.4314/tjpr.v20i2.14

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the effect of diosmetin on young, non-alcoholic fatty liver disease (NAFLD) rats.

Methods: Five groups of SD rats were used: control group, high-fat diet group, low-dose diosmetin group, medium-dose diosmetin group, and high-dose diosmetin group, each with 10 rats. After 3 months, interleukin 6 (IL-6), IL-1β) and TNF-α) were assayed. Protein expressions of p-AMPKα, CPT-1 and PPAR-α, AMPKα, SREBP-1c and FAS were assayed.

Results: In the high-fat diet group, the levels of p-AMPKα, CPT-1 and PPAR-α were lower than the corresponding control values, while p-AMPKα, CPT-1 and PPAR-α levels were dose-dependently higher in all diosmetin groups than in NAFLD group (p < 0.05). There were higher levels of SREBP-1c and FAS in the high-fat diet group than in control group, while SREBP-1c and FAS levels in all diosmetin groups were dose-dependently lower than the corresponding levels in NAFLD group. Serum IL-6, IL-1β and TNF-α levels in NAFLD group were raised, relative to control values (p < 0.05).

Conclusion: Diosmetin alleviates NAFLD lesions induced by high-fat diet, slows down liver cell apoptosis, and inhibits inflammation via activation of AMPK pathway. Thus, diosmetin has potentials for use in the repair of hepatic damage induced by high-fat diet

Keywords: Diosmetin, High-fat diet, Nonalcoholic fatty liver disease, NAFLD